443093-86-5

Basic information

• Product Name: (2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid
• Synonyms: N-[(2'-Cyanobiphenyl-4-yl)methyl]-N-pentanoyl-L-valine
• CAS NO: 443093-86-5
• Molecular Formula: C₂₄H₂₈N₂O₃
• Molecular Weight: 392.49
• Mol File: 443093-86-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 613.2°C at 760 mmHg
• Flash Point: 324.6°C
• Density: 1.16g/cm³
• Vapor Pressure: 6.86E-16mmHg at 25°C
• Refractive Index: 1.581
• CAS DataBase Reference: (2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid(443093-86-5)
• EPA Substance Registry System: (2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid(443093-86-5)

Safety Data

• Hazardous Substances Data: 443093-86-5(Hazardous Substances Data)

Usage

Description

(2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid is a complex amino acid with a unique arrangement of atoms, including a pentanoyl-amino group attached to a 3-methyl-butanoic acid backbone. It also features a 2-cyanophenyl group and a 4-phenyl group, contributing to its overall structure and properties.

Uses

Used in Pharmaceutical Industry:
(2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid is used as a pharmaceutical compound for its potential applications in drug development and therapeutics.
Used in Biochemistry Research:
(2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid is used as a research tool in biochemistry to study its biological and chemical properties, which could provide valuable insights into its potential applications.
Used in Organic Synthesis:
(2S)-2-[[4-(2-cyanophenyl)phenyl]methyl-pentanoyl-amino]-3-methyl-butanoic acid is used as a building block in organic synthesis for the development of new compounds and materials.

Upstream product

• 137863-90-2 methyl 2-(N-((2'-cyanobiphenyl-4-yl)methyl)pentanamido)-3-methylbutanoate 
• 137864-22-3 (S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyric acid benzyl ester 
• 1298055-63-6 C₂₉H₃₆N₂O₃ 
• 638-29-9 n-valeryl chloride 
• 1189547-11-2 methyl N-pentanoyl-L-valinate 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERTENSION AND MANAGEMENT OF DIABETIC KIDNEY DISEASE

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing hypertension and diabetic kidney disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes related renal complications, hypertension, albuminuria, Heart Diseases, ESRD, Kidney GFR complications, Vascular Disease, Ventricular Septal Defect, vascular dilation, high blood pressure, congestive heart failure (CHF), post-myocardial infarction (MI).

Process for the manufacture of organic compounds

The present invention relates to a process for the manufacture of an angiotensin receptor blocker (ARB: also called angiotension II receptor antagonist or AT1 receptor antagonist) and salts, thereof, to novel intermediates and process steps.

Process for the preparation of valsartan and intermediates thereof

A novel process for the preparation of valsartan and novel intermediates useful in the preparation thereof.